Literature DB >> 29434895

Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.

Dongsheng Wang1, Bei Zhong2, Yu Li1, Xiaodong Liu1.   

Abstract

As a derivative of artemisinin, dihydroartemisinin is effective in the treatment of malaria. Dihydroartemisinin has been identified to possess inhibitory effects in numerous types of animal model with tumors, indicating that it has an antineoplastic effect. The aim of the present study was to analyze the potential anticancer effects of dihydroartemisinin, particularly its effect on apoptosis of colon cancer cells. In the present study, it was identified that dihydroartemisinin inhibited cell viability, promoted cell apoptosis, increased B-cell lymphoma-2-associated X-protein expression, increased caspase-3/9 activities, decreased poly(ADP-ribose) polymerase levels, decreased phosphorylation of extracellular-signal-regulated kinase, and increased phosphorylation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase in colon cancer cells. Conversely, the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) was suppressed by dihydroartemisinin in colon cancer cells. These results demonstrate that the potential anticancer effects of dihydroartemisinin may increase apoptosis of colon cancer cells through targeting JAK2/STAT3 signaling.

Entities:  

Keywords:  Janus kinase 2; apoptosis; colon cancer; dihydroartemisinin; signal transducer and activator of transcription 3

Year:  2017        PMID: 29434895      PMCID: PMC5776939          DOI: 10.3892/ol.2017.7502

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial.

Authors:  Franck Monnien; Harouna Zaki; Christophe Borg; Christiane Mougin; Jean-François Bosset; Mariette Mercier; Francine Arbez-Gindre; Bernadette Kantelip
Journal:  J Clin Pathol       Date:  2010-10       Impact factor: 3.411

2.  Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).

Authors:  Sotaro Sadahiro; Satoshi Morita; Kazuaki Sasaki; Kazuhiro Sakamoto; Hiroki Ohge; Takao Takahashi; Takashi Tsuchiya; Toshihiko Sato; Ken Kondo; Yutaka Ogata; Hiroyuki Masuko; Hideo Baba; Kiyoshi Maeda; Madoka Hamada; Michio Itabashi; Genichi Nishimura; Keiichi Takahashi; Masataka Ikeda; Masataka Taguri; Susumu Kodaira
Journal:  Clin Colorectal Cancer       Date:  2015-05-22       Impact factor: 4.481

3.  Dihydroartemisinin induces apoptosis in human gastric cancer cell line BGC-823 through activation of JNK1/2 and p38 MAPK signaling pathways.

Authors:  Shuyi Zhang; Lei Shi; Hongwen Ma; Hongzhou Li; Yanru Li; Ying Lu; Qiaoping Wang; Wen Li
Journal:  J Recept Signal Transduct Res       Date:  2016-07-12       Impact factor: 2.092

4.  Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.

Authors:  Hua Xiong; Wan Du; Yan-Jie Zhang; Jie Hong; Wen-Yu Su; Jie-Ting Tang; Ying-Chao Wang; Rong Lu; Jing-Yuan Fang
Journal:  Mol Carcinog       Date:  2011-04-22       Impact factor: 4.784

5.  S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.

Authors:  Satoru Iwasa; Kengo Nagashima; Tatsuro Yamaguchi; Hiroshi Matsumoto; Yasushi Ichikawa; Ayumu Goto; Hisateru Yasui; Ken Kato; Natsuko Tsuda Okita; Yasuhiro Shimada; Yasuhide Yamada
Journal:  Cancer Chemother Pharmacol       Date:  2015-07-29       Impact factor: 3.333

6.  MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Authors:  Lucio Tentori; Alessia Muzi; Annalisa Susanna Dorio; Susanna Dolci; Federica Campolo; Patrizia Vernole; Pedro Miguel Lacal; Françoise Praz; Grazia Graziani
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-01       Impact factor: 3.333

7.  Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity.

Authors:  Zeng Wang; Wei Hu; Jia-Li Zhang; Xiu-Hua Wu; Hui-Jun Zhou
Journal:  FEBS Open Bio       Date:  2012-05-23       Impact factor: 2.693

8.  Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Authors:  Jalaj Gupta; Ana Igea; Marilena Papaioannou; Pedro Pablo Lopez-Casas; Elisabet Llonch; Manuel Hidalgo; Vassilis G Gorgoulis; Angel R Nebreda
Journal:  Oncotarget       Date:  2015-04-20

9.  Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia.

Authors:  Katarzyna Neubauer; Iwona Bednarz Misa; Dorota Diakowska; Bartosz Kapturkiewicz; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Biomed Res Int       Date:  2015-05-13       Impact factor: 3.411

10.  Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Authors:  E Sanchez-Lopez; E Flashner-Abramson; S Shalapour; Z Zhong; K Taniguchi; A Levitzki; M Karin
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more
  8 in total

Review 1.  Malaria and Cancer: a critical review on the established associations and new perspectives.

Authors:  Toby Ellis; Elvis Eze; Bahijja Tolulope Raimi-Abraham
Journal:  Infect Agent Cancer       Date:  2021-05-13       Impact factor: 2.965

2.  Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer.

Authors:  Bingjun Bai; Fei Wu; Kangkang Ying; Yuzi Xu; Lina Shan; Yiming Lv; Xing Gao; Dengyong Xu; Jun Lu; Binbin Xie
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

3.  SRF Potentiates Colon Cancer Metastasis and Progression in a microRNA-214/PTK6-Dependent Manner.

Authors:  Tao Li; Yingchun Wan; Ziyuan Su; Jiayu Li; Minna Han; Changyu Zhou
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.602

4.  A Novel Antimalarial Metabolite in Erythrocyte From the Hydroxylation of Dihydroartemisinin by Cunninghamella elegans.

Authors:  Yue Bai; Yifan Zhao; Xinna Gao; Dong Zhang; Yue Ma; Lan Yang; Peng Sun
Journal:  Front Chem       Date:  2022-04-26       Impact factor: 5.545

5.  Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis.

Authors:  Qiuting Zhang; Huimei Yi; Hui Yao; Lu Lu; Guangchun He; Mi Wu; Chanjuan Zheng; Ying Li; Sisi Chen; Lewei Li; Hongyuan Yu; Guifei Li; Xiaojun Tao; Shujun Fu; Xiyun Deng
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 6.  Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.

Authors:  Sankhadip Bose; Sabyasachi Banerjee; Arijit Mondal; Utsab Chakraborty; Joshua Pumarol; Courtney R Croley; Anupam Bishayee
Journal:  Cells       Date:  2020-06-11       Impact factor: 6.600

Review 7.  Antitumor Research on Artemisinin and Its Bioactive Derivatives.

Authors:  Yunqin Zhang; Guowei Xu; Shuqun Zhang; Dong Wang; P Saravana Prabha; Zhili Zuo
Journal:  Nat Prod Bioprospect       Date:  2018-04-09

Review 8.  Dihydroartemisinin: A Potential Natural Anticancer Drug.

Authors:  Xiaoshuo Dai; Xiaoyan Zhang; Wei Chen; Yihuan Chen; Qiushuang Zhang; Saijun Mo; Jing Lu
Journal:  Int J Biol Sci       Date:  2021-01-16       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.